Navigation Links
Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update
Date:11/12/2013

ROCKVILLE, Md., Nov. 12, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported  financial results for the three months and nine months ended September 30, 2013 and provided a business and clinical update.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"The Company reached several major milestones in the third quarter. We completed patient dosing in our Phase Ib trial to treat major depressive disorder with NSI-189, our lead small molecule compound. We also commenced a multicenter Phase II cell therapy trial with NSI-566 to treat ALS, and completed dosing of all patients in the first cohort," said Karl Johe, PhD, Neuralstem's Chairman of the Board and Chief Scientific Officer. "The dose escalation trial for NSI-189 advanced through three cohorts of eight depression patients each, with the final cohort receiving three daily doses of 40 mg for 28 days. During the coming months we will be compiling the data from this Phase I study.

"We are particularly excited to have begun our Phase II ALS dose escalation trial, treating the first cohort of three patients in the cervical region of the spinal cord. We are currently treating the second of five cohorts and hope to transplant all 15 patients by the completion of the second quarter of 2014," continued Dr. Johe. "We are pleased that principal investigator Dr. Eva Feldman, added the University of Michigan Health System, where she is Director of Research of the ALS Clinic and Director of the A. Alfred Taubman Medical Research Institute, as a second trial center. We are working towards adding a third site, Massachusetts General, in the coming months. The Phase II trial protocol calls for increased dosing and a maximum of 40 injections and up to 400,000 cells per injection, with a one-month observation period between each cohort.

"Dr. Feldman, who is also the president of the American Neu
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
10. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
11. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... TAI,AN, Shandong, China, Sept. ... Bulletin Board: CBPO) ("China Biologic," or the,"Company"), ... in the,People,s Republic of China ("PRC"), operating ... Products Co. Ltd.,("Taibang") and Chongqing Dalin Biologic ...
... CORK, Ireland, September 10 Hovione announced today that,Terry Lambe, ... Ltd. , Hovione acquired earlier this year ... element of the Hovione strategy to become a,leading manufacturer to the ... welcome Terry Lambe to Hovione. We want to build our,Cork site ...
... ROTTERDAM, The Netherlands, September 10 arGEN-X ... human,antibodies using its proprietary SIMPLE Antibody(TM) platform, today,announced the successful ... raised EUR 9.5million ( USD 13.6 million) from a,syndicate of ... largest of its kind in the last 12 months. , ...
Cached Biology Technology:China Biologic Products to Attend at Susquehanna's Third Annual Beijing Management Summit 2China Biologic Products to Attend at Susquehanna's Third Annual Beijing Management Summit 3Hovione Appoints Terry Lambe to its Board of Directors 2arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work 2arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work 3arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work 4arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work 5
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... de Physiologie Neurovg tative (CNRS-INRA-Universit Paul C zanne), the ... and from the D partement Lipoprotines et M ... Professor Jean-Pierre Miolan, Dr Jean-Pierre Niel, Directeur de Recherche ... Dr Abel Hiol Ma tre de confrence and ...
... international research team, including biologists from NOAA Fisheries Service, ... had failed to find a single Yangtze River dolphin, ... scientists fear the marine mammal is now extinct due ... the first cetacean to vanish as result of human ...
... Springer, one of the worlds leading STM publishers, will ... publication of the EUCC the Coastal Union. ... to Springers other journals in coastal science, the International ... The first issue of the relaunched JCCO, with ...
Cached Biology News:Scientists fear rare dolphin driven to extinction by human activities 2Springer will publish Journal of Coastal Conservation 2
muscle actin (HUC1-1)...
Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
... Anti-NY-ESO-1, clone E978 ... NM_001327 Immunogen : ... Formulation: mouse ascites with ... Assurance: routinely evaluated by ...
... Opsin 1 ( Abpromise for all tested ... YEDSTHASIFTYT, corresponding to amino acids 14/26 of Mouse ... to amino acids 18/30 of tiger red cones ... Entrez Gene ID: 5956 ...
Biology Products: